S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Toby Neugebauer Schedules Live Town Hall Following Proxy Advisor Support

Following recommendations from Glass Lewis and Egan-Jones to support a special shareholder meeting, Fermi Inc. co-founder Toby Neugebauer will host a live, unscripted webinar tomorrow, June 30, at 4:00 PM ET. The session aims to address analyst inquiries regarding the company's governance and future direction.

Toby Neugebauer Schedules Live Town Hall Following Proxy Advisor Support
Photo: Bio & News

The advisory firms' backing of Neugebauer's GREEN consent card marks a significant shift in his ongoing campaign to force a special meeting at Fermi. Glass Lewis cited the company’s failure to hold an annual meeting as a primary justification for supporting the request, while Egan-Jones emphasized the necessity of providing shareholders with a clear mechanism to influence board composition and strategic policy.

Despite formal invitations, Fermi leadership—specifically Governor Rick Perry, Griffin Perry, and COO Jacobo Ortiz—have declined to participate in the upcoming forum. Neugebauer intends to proceed with the event regardless, positioning the session as an effort to inject transparency into a dispute that recently saw him secure a court victory involving the discovery of company documents. Shareholders and analysts are encouraged to register for the session, where Neugebauer plans to field live questions on the record to clarify his perspective on the company’s trajectory.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!